Source: Streetwise Reports 08/10/2022
The latest data from Emerita Resources Corp. may support growth of the company’s overall project resource, noted a Clarus Securities report.
reported additional positive drill results from its Romanera and La Infanta base metal deposits in Spain, reported Clarus Securities analyst Varun Arora in an August 4, 2022 research note.
“Overall, we are encouraged by the drill results that continue to expand both Romanera and La Infanta, which may support significantly expanding the resource at [the] Iberian Belt West towards +30,000,000 tons with continued expansion drilling success versus our currently modelled ~21,000,000 tons,” Arora wrote and reviewed the drill results from both deposits.
Drilling at Romanera, noted Arora, “continues to return strongly economic results (up to US$477 per ton in situ value included in LR005) with wide and high grade intercepts.”
LR005, one of the two holes reported, cut both the upper and lower lenses. In the upper lens, it returned 16.4% zinc equivalent (Zn eq) or 8.47 grams per ton gold equivalent (8.47 g/t Au eq) over 7 meters (7m) from 117m downhole. In the lower lens, LR005 demonstrated 13.5% Zn eq or 6.97 g/t Au eq over 16.9m.
Initial stepout drilling at Romanera, consisting of hole LR007 placed 100m east of historical drilling, showed the mineralization continues in that direction. The returned widths and grades of the intercepts there, though, do not stand out. A significant intercept was 6.4% Zn eq (with 3.7% copper) over 7m from 547m downhole.
“It’s possible that the mineralization pinches and swells, and so it’s possible we will see wider and higher grade intercepts with continued drilling outside the historic footprint,” Arora wrote, adding that the deposit remains open along strike and at depth.
Adam Schatzker, analyst at Research Capital Corp., also commented on the new drill results from both Emerita deposits, in an Aug. 4 report.
He noted the Romanera results confirm but exceed the historical figures, given the new gold and silver values are better than expected.
“Romanera is developing well for its stage of exploration,” wrote Schatzker.
Results from La Infanta, on the other hand, Schatzker indicated, were “mixed with some narrow, high-grade hits and a small number of wider high-grade intercepts.” He added that La Infanta is “losing momentum” and he expects Emerita to cut back on its exploration work there.
Clarus Securities and Research Capital rate Emerita Speculative Buy. As for price targets on the natural resource company, Clarus’ is CA$5 per share, Research Capital’s is CA$4. In comparison, Emerita is currently trading at CA$1.03 per share.
1) Doresa Banning wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: here for important disclosures about sponsor fees. As of the date of this article, an affiliate of Streetwise Reports has a consulting relationship with None. Please click here for more information.Click
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the decision to publish an article until three business days after the publication of the article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
Disclosures for Clarus Securities,, Aug. 4, 2022
The analyst has visited the Company’s operations in Spain in November 2021. Partial payment or reimbursement was received from the
issuer for the associated travel costs. Within the last 24 months, Clarus Securities Inc. has managed or co-managed a public offering of securities of this company. Within the last 24 months, Clarus Securities Inc. has received compensation for investment banking services with respect to the securities of this company.
The information and opinions in this report were prepared by Clarus Securities Inc. (“Clarus Securities”). Clarus Securities is a whollyowned subsidiary of Clarus Securities Holdings Ltd. and is an affiliate of such. The reader should assume that Clarus Securities or its affiliate
may have a conflict of interest and should not rely solely on this report in evaluating whether or not to buy or sell securities of issuers
The opinions, estimates and projections contained in this report are those of Clarus Securities as of the date of this report and are subject
to change without notice. Clarus Securities endeavours to ensure that the contents have been compiled or derived from sources that we
believe are reliable and contain information and opinions that are accurate and complete. However, Clarus Securities makes no
representation or warranty, express or implied, in respect thereof, takes no responsibility for any errors and omissions contained herein
and accepts no liability whatsoever for any loss arising from any use of, or reliance on, this report or its contents. Information may be
available to Clarus Securities or its affiliate that is not reflected in this report. This report is not to be construed as an offer or solicitation to
buy or sell any security. No part of this report may be reproduced or re-distributed without the written consent of Clarus Securities.
Conflicts of Interest: The research analyst and/or associates who prepared this report are compensated based upon (among other factors) the overall
profitability of Clarus Securities and its affiliate, which includes the overall profitability of investment banking and related services. In the normal course of its business, Clarus Securities or its affiliate may provide financial advisory and/or investment banking services for the issuers mentioned in this report in return for remuneration and might seek to become engaged for such services from any of such issuers in this report within the next three months. Clarus Securities or its affiliate may buy from or sell to customers the securities of issuers mentioned in this report on a principal basis. Clarus Securities, its affiliate, and/or their respective officers, directors or employees may from time to time acquire, hold or sell securities discussed herein, or in related securities or in options, futures or other derivative instruments based thereon.
Analyst’s Certification: Each Clarus Securities research analyst whose name appears on the front page of this research report hereby certifies that (i) the recommendations and opinions expressed in the research report accurately reflect the research analyst’s personal views about the Company and securities that are the subject of this report and all other companies and securities mentioned in this report that are covered by such research analyst and (ii) no part of the research analyst’s compensation was, is, or will be directly or indirectly, related to the specific recommendations or views expressed by such research analyst in this report.
Disclosures for Research Capital Corp.,, Aug. 4, 2022
Analyst Certification: I, Adam Schatzker, certify the views expressed in this report were formed by my review of relevant company data and industry
investigation, and accurately reflect my opinion about the investment merits of the securities mentioned in the report. I also certify that my compensation is not related to specific recommendations or views expressed in this report. Research Capital Corporation publishes research and investment recommendations for the use of its clients. Information regarding our categories of recommendations, quarterly summaries of the percentage of our recommendations which fall into each category and our policies regarding the release of our research reports is available at www.researchcapital.com or may be requested by contacting the analyst. Each analyst of Research Capital Corporation whose name appears in this report hereby certifies that (i) the recommendations and opinions expressed in this research report accurately reflect the analyst’s personal views and (ii) no part of the research analyst’s compensation was or will be directly or indirectly related to the specific conclusions or recommendations expressed in this research report.
Adam Schatzker has visited Emerita Resources Corp. in the past 18 months.
General Disclosures: The opinions, estimates and projections contained in all Research Reports published by Research Capital Corporation (“RCC”) are those of RCC as of the date of publication and are subject to change without notice. RCC makes every effort to ensure that the contents have been compiled or derived from sources believed to be reliable and that contain information and opinions that are accurate and complete; RCC makes no representation or warranty, express or implied, in respect thereof, takes no responsibility for any errors and omissions which may be contained therein and accepts no liability whatsoever for any loss arising from any use of or reliance on its Research Reports or its contents. Information may be available to RCC that is not contained therein. Research Reports disseminated by RCC are not a solicitation to buy or sell. All securities not available in all jurisdictions.
Potential Conflicts of Interest: All Research Capital Corporation (“RCC”) Analysts are compensated based in part on the overall revenues of RCC, a portion of which are generated by investment banking activities. RCC may have had, or seek to have, an investment banking relationship with companies mentioned in this report. RCC and/or its officers, directors and employees may from time to time acquire, hold or sell securities mentioned in our Research Reports as principal or agent. RCC makes every effort possible to avoid conflicts of interest, however readers should assume that a conflict might exist, and therefore not rely solely on this report when evaluating whether or not to buy or sell the securities of subject companies.
RCC USA: Information about Research Capital Corporation’s Rating System, the distribution of our research to clients and the percentage of recommendations which are in each of our rating categories is available on our website at www.researchcapital.ca. The information contained in this report has been drawn from sources believed to be reliable but its accuracy or completeness is not guaranteed, nor in providing it does Research Capital Corporation assume any responsibility or liability. Research Capital Corporation, its directors, officers and other employees may, from time to time, have positions in the securities mentioned herein. Contents of this report cannot be reproduced in whole or in part without the express permission of Research Capital Corporation. US Institutional Clients – Research Capital USA Inc., a wholly owned subsidiary of Research Capital Corporation, accepts responsibility for the contents of this report subject to the terms and limitations set out above. US firms or institutions receiving this report should effect transactions in securities discussed in the report through Research Capital USA Inc., a Broker – Dealer registered with the Financial Industry Regulatory Authority (FINRA).
( Companies Mentioned: EMO:TSX.V; EMOTF:OTCMKTS; LLJ:FSE, )
Please Help Support BeforeitsNews by trying our Natural Health Products below!
Order by Phone at 888-809-8385 or online at https://mitocopper.com M - F 9am to 5pm EST
Order by Phone at 866-388-7003 or online at https://www.herbanomic.com M - F 9am to 5pm EST
Order by Phone at 866-388-7003 or online at https://www.herbanomics.com M - F 9am to 5pm EST
Humic & Fulvic Trace Minerals Complex - Nature's most important supplement! Vivid Dreams again!
HNEX HydroNano EXtracellular Water - Improve immune system health and reduce inflammation
Ultimate Clinical Potency Curcumin - Natural pain relief, reduce inflammation and so much more.
pathogens and gives you more
energy. (See Blood Video)
Oxy Powder - Natural Colon Cleanser! Cleans out toxic buildup with oxygen!
Nascent Iodine - Promotes detoxification, mental focus and thyroid health.
Smart Meter Cover - Reduces Smart Meter radiation by 96%! (See Video)